Suddenly consolidation and vertical integration-related woes seem like issues of a distant past for the entire drug channel. In the age of the global COVID-19 pandemic, numerous valid concerns have been raised relative to the durability and defensibility of the drug supply chain, particularly in the U.S. To understand these concerns, Coleman hosted a call with one of our top healthcare experts to substantiate a most thoughtful discussion and address all key questions on the tips of investor’s tongues as go-forward business practices will undoubtedly soon undergo a dramatic, lasting transformation.
This call was hosted on March 31, 2020, under the title: “(MCK, ABC, CAH, TEVA) – COVID-19 & The Global Drug Supply Chain: Distributors & Manufacturers.”
You can request a replay & transcript of the Hosted Event discussed above, or any of our Hosted Events, by emailing [email protected].
Coleman Research Group, Inc. (“Coleman” or the “Firm”) sponsors events featuring a wide range of speakers (“Guest Speakers”). The opinions, estimates, projections, and views contained in this summary are those of, and exclusively sourced from, the Guest Speakers and are not reviewed or endorsed by the Guest Speakers. In respect of this summary, Coleman makes no representation or warranty, express or implied, is not providing investment, legal, tax, financial, or accounting advice, and accepts no liability whatsoever. Coleman retains sole discretion as it relates to accessing this information by clients and prospective clients.